RESUMEN
SUMMARY: This study aims to investigate the effect of Tangzhouling on the morphological changes of Nissl bodies in the dorsal root ganglion of DM Rats. In this study, 69 rats were randomly divided into a control group (n = 10) and a model group (n = 59). The rats in the model group were randomly divided into a diabetic group (n = 11), a vitamin C group (n = 12), a low dose Tangzhouling group (n = 12), a medium dose Tangzhouling group (n = 12) and a high dose Tangzhouling group (n = 12). The dose of Tangzhouling in the low dose group was 5 times that of the adult dose, being 0.44g/kg/d. The dose of Tangzhouling in the medium dose group was 10 times that of the adult dose, being 0.88g/kg/d. The dose of Tangzhouling in the high dose group was 20 times that of the adult dose, being 1.75g/kg/d. All doses above are crude drug dosages. Rats in the vitamin C group were given 10 times the dose of an adult, being, 0.05 g/ kg/d. The diabetic group and the control group were given the same amount of distilled water. Drug delivery time is 16 weeks. The dorsal root ganglion was placed in a freezing tube at the end of the experiment. The morphological changes of Nissl bodies in the dorsal root ganglion were detected by HE and Nissl staining. The study results showed that vitamin C had no significant effect on the quantity, size and nucleolus. Tangzhouling can improvee the morphology, quantity and nucleolus of Nissl bodies to a certain extent, and the high dose is better than the lower dose. Tangzhouling capsules can improve the nerve function of DM rats through Nissl bodies.
RESUMEN: Este estudio tuvo como objetivo investigar el efecto de Tangzhouling en los cambios morfológicos de los cuerpos de Nissl en el ganglio de la raíz dorsal de las ratas DM. En este estudio, 69 ratas se dividieron aleatoriamente en un grupo control (n = 10) y un grupo modelo (n = 59). Las ratas del grupo modelo se dividieron aleatoriamente en un grupo diabéticos (n = 11), un grupo vitamina C (n = 12), un grupo de dosis baja de Tangzhouling (n = 12), un grupo de dosis media de Tangzhouling (n = 12) y un grupo de dosis alta de Tangzhouling (n = 12). La dosis de Tangzhouling en el grupo de dosis baja fue 5 veces mayor que la dosis del adulto, siendo 0,44 g/kg/d. La dosis de Tangzhouling en el grupo de dosis media fue 10 veces mayor que la dosis del adulto, siendo 0,88 g/kg/d. La dosis de Tangzhouling en el grupo de dosis alta fue 20 veces mayor que la dosis del adulto, siendo 1,75 g/kg/d. Todas las dosis anteriores son dosis de fármaco crudo. Se les administró 10 veces la dosis de un adulto a las ratas del grupo vitamina C, siendo 0,05 g/kg/d. El grupo de diabéticos y el grupo de control recibieron la misma cantidad de agua destilada. El tiempo de entrega del fármaco fue de 16 semanas. El ganglio de la raíz dorsal se colocó en un tubo de congelación al final del experimento. Los cambios morfológicos de los cuerpos de Nissl en el ganglio de la raíz dorsal se detectaron mediante tinción de HE y Nissl. Los resultados del estudio mostraron que la vitamina C no tuvo un efecto significativo sobre la cantidad, el tamaño y el nucléolo. Tangzhouling puede mejorar la morfología, la cantidad y el nucléolo de los cuerpos de Nissl hasta cierto punto, y es mejor la dosis alta que la dosis baja. Las cápsulas de Tangzhouling pueden mejorar la función nerviosa de las ratas DM a través de los cuerpos de Nissl.
Asunto(s)
Animales , Ratas , Enfermedades del Sistema Nervioso Periférico , Neuropatías Diabéticas , Ganglios Espinales/efectos de los fármacos , Cuerpos de Nissl/efectos de los fármacos , Coloración y Etiquetado , Modelos Animales de EnfermedadRESUMEN
OBJECTIVE: To evaluate the effect and safety of HbA1c and glycemic control of acarbose chewable tablets in patients with type 2 diabetic. METHOD: A multicentre, randomized, double-blinded, double-dummy, positive controlled clinical trial was conducted. Two hundred thirty-four Chinese patients with type 2 diabetic were enrolled in eight clinical centres, who were divided randomly into the acarbose chewable tablet group (experimental group, n = 116) and the acarbose treatment group (control group, n = 118). RESULTS: Two hundred seven patients (88.5%) took part in the 12-week trial. At the beginning and end of the clinical trial, HbA1c and blood glucose as well as safety indexes were measured. After the treatment, the level of finger two-hour postprandial blood glucose (PPBG) was decreased 4.15 mmol/L (26.82%) and 3.54 mmol/L (22.77%), respectively, in the experiment group and the control group. The levels of venous two-hour PPBG in the experiment group and the control group were decreased 4.04 mmol/L (25.38%) and 2.75 mmol/L (17.26%), respectively, with the means of HbA1c lowering 11.67% and 12.44%, respectively. Fasting blood glucose (FBG) also was reduced significantly in both groups. Patients in both groups showed obvious weight reduction (P < 0.0001). There were no significant differences in the incidence of adverse events between the two groups. CONCLUSION: In summary, acarbose chewable tablets have a definite curative effect in treating type 2 diabetic patients as HbA1c and blood glucose levels decreased significantly after the 12-week treatment.
Asunto(s)
Acarbosa/uso terapéutico , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Hipoglucemiantes/uso terapéutico , Acarbosa/efectos adversos , Glucemia/análisis , Método Doble Ciego , Hemoglobina Glucada/análisis , Humanos , Hipoglucemiantes/efectos adversosRESUMEN
OBJECTIVE: To study the effects of Liuweidihuang pills on pancreatic islet structure in OLETF (Otsuka Long-Evans Tokushima Fatty) rats. METHODS: Forty male OLETF rats were divided randomly into Liuweidihuang pills group (Liuwei group) and control group (n=20). Ten male LETO rats were used as normal control group (LETO group). The rats in Liuwei group were given Liuweidihuang pills at the daily dose of 2.4 mg/kg intragastrically since the age of 8 weeks. Blood glucose was determined by OGTT. The rats were sacrificed at 8, 32 and 40 weeks and the pancreatic tissue was isolated to examine the morphological changes of the pancreas by HE staining and Masson trichrome staining. RESULTS: As the age of the rats increased, the pancreatic islets in the control group gradually showed fibrosis and islet atrophy, which were not found in Liuwei group. Masson staining visualized no fibrosis in Liuwei group. No significant pathological change occurred in the pancreatic islet of LETO rats. The rats in Liuwei group developed diabetes since 30 weeks of age and the incidence was 28.6% at 40 weeks, significantly lower than that in the control group (P<0.01). CONCLUSION: Liuweidihuang pills can prevent degeneration of the pancreatic islets in spontaneous OLETF rats.
Asunto(s)
Diabetes Mellitus Tipo 2/tratamiento farmacológico , Diabetes Mellitus Tipo 2/patología , Medicamentos Herbarios Chinos/uso terapéutico , Islotes Pancreáticos/patología , Animales , Masculino , Fitoterapia , Sustancias Protectoras/uso terapéutico , Distribución Aleatoria , Ratas , Ratas Endogámicas OLETFRESUMEN
OBJECTIVE: To study the effects of Liuweidihuang pills in preventing diabetes in Otsuka Long-Evans Tokushima Fatty (OLETF) rats. METHODS: Forty male OLETF rats were randomized equally into Liuweidihuang pill group and control group, with 10 male LETO rats as the normal control group. In Liuweidihuang pill group, the rats were given the pills intragastrically at the daily dose of 2.4 mg/kg since 8 weeks of age, and the rats in the other two groups received water instead. Blood glucose of the rats was determined by oral glucose tolerance test (OGTT), and the body weight and food intake were monitored on a weekly basis. At 8, 32 and 40 weeks, the rats were sacrificed and the expression level of adiponectin mRNA in the adipose tissue was detected using RT-PCR. RESULTS: Treatment with Liuweidihuang pills significantly lowered the increment of the blood glucose and postponed the onset of hyperglycemia in the rats. Compared with the control group, the rats in Liuweidihuang pill group showed significantly increased expression of adiponectin mRNA in the adipose tissue. The rats receiving Liuweidihuang pills developed diabetes at 30 weeks of age with an incidence of 28.6% at 40 weeks, significantly lower than that in the control group (P<0.01). CONCLUSION: Liuweidihuang pills can significantly increase the expression of adiponectin mRNA in the adipose tissue and decrease the incidence of type 2 diabetes in OLETF rats.
Asunto(s)
Diabetes Mellitus Experimental/prevención & control , Medicamentos Herbarios Chinos/uso terapéutico , Fitoterapia , Adiponectina/genética , Adiponectina/metabolismo , Tejido Adiposo/metabolismo , Animales , Glucemia/metabolismo , Masculino , ARN Mensajero/genética , ARN Mensajero/metabolismo , Distribución Aleatoria , Ratas , Ratas Endogámicas OLETFRESUMEN
OBJECTIVE: To study the effects of Liuweidihuang (LWDH) pills on plasma adiponectin level in Otsuka Long-Evans Tokushima Fatty (OLETF) rats. METHODS: Forty male OLETF rats were randomized into LWDH and control OLETF groups (n=20), and 10 male Long-Evans Tokushima Otsuka (LETO) rats served as the normal control group (LETO group). The rats in LWDH group were given LWDH pills (daily dose of 2.4 mg/kg) intragastrically since the age of 8 weeks, and the two control groups received water only. Regular blood glucose test was performed using oral glucose tolerance test, and the body weight and food intake of the rats were recorded on a weekly basis. At 8, 32 and 40 weeks of age, respectively, the rats were sacrificed for measurement of plasma adiponectin and plasma insulin. RESULTS: The food intake of the OLETF rats in both groups were significantly greater than the LETO rats (P<0.01). The rats in LWDH group developed diabetes since 30 weeks of age with an incidence of 28.6% at 40 weeks, which was significantly lower than that in the control OLETF rats (P< 0.01). CONCLUSION: Plasma adiponectin level is positively correlated to insulin sensitivity in OLETF rats, in which LWDH pills can increase the plasma level of adiponectin and improve the status of insulin resistance.
Asunto(s)
Adiponectina/sangre , Diabetes Mellitus Tipo 2/sangre , Medicamentos Herbarios Chinos/farmacología , Resistencia a la Insulina , Animales , Diabetes Mellitus Tipo 2/fisiopatología , Diabetes Mellitus Tipo 2/prevención & control , Ingestión de Alimentos/efectos de los fármacos , Hipoglucemiantes/farmacología , Insulina/sangre , Masculino , Distribución Aleatoria , Ratas , Ratas Endogámicas OLETF , Ratas Long-EvansRESUMEN
OBJECTIVE: To investigate the effects of Liuweidihuang pills (LP) on visceral fat deposition in Otsuka Long-Evans Tokushima Fatty (OLETF) rats. METHODS: Forty male OLETF rats were randomly divided into LP group and control group (n=20 per group), and 10 male Long-evans Tokushima Otsuka (LETO) rats were used as normal controls. The rats in LP group were given LP(2.4 mg/kg) daily by intragastric administration since the age of 8 weeks, and those in the other two groups were given water of the same volume by intragastric administration. Blood glucose of all the rats was determined by oral glucose tolerance test (OGTT) and visceral fat deposition examined after the rats were sacrificed. RESULTS: OLETF rats had obviously greater amount of visceral fat than LETO rats (P<0.05) and administration of LP ameliorated the increment of visceral fat deposition in this type 2 diabetic model, producing significant effect at the age of 40 weeks (P<0.01). CONCLUSION: LP may effectively decrease visceral fat deposition in OLETF rats.
Asunto(s)
Diabetes Mellitus Tipo 2/tratamiento farmacológico , Medicamentos Herbarios Chinos/uso terapéutico , Grasa Intraabdominal/efectos de los fármacos , Animales , Glucemia/metabolismo , Diabetes Mellitus Tipo 2/sangre , Diabetes Mellitus Tipo 2/patología , Grasa Intraabdominal/patología , Masculino , Obesidad/patología , Obesidad/prevención & control , Fitoterapia , Distribución Aleatoria , Ratas , Ratas Endogámicas OLETFRESUMEN
OBJECTIVE: To investigate the effects of Liuwei Dihuang Pills (LWDHP) on expressions of apoptosis-related genes bcl-2 and Bax in pancreas of OLETF rats. METHODS: Forty male OLETF rats were randomly divided into LWDHP-treated group and untreated group. Another ten male LETO rats were included in normal control group. OLETF rats in the LWDHP-treated group were given LWDHP (2.4 g.kg(-1).d(-1)) orally since the age of 8 weeks and the rats in the other two groups were given distilled water orally. Body weights of rats were recorded weekly and blood glucose concentration was determined by oral glucose tolerance test (OGTT). Pancreas weights were recorded after rats were killed and the expression levels of bcl-2 mRNA and Bax mRNA were detected by reverse transcriptase-polymerase chain reaction (RT-PCR). RESULTS: In the LWDHP-treated group, the expression of bcl-2 mRNA in the pancreas of rats at the age of 40 weeks (1.25+/-0.07) was much higher than that in the untreated group (1.01+/-0.16), P<0.01. Bax mRNA level in the LWDHP-treated group (0.57+/-0.11) was obviously lower than that in the untreated group (1.18+/-0.28), P<0.01. There was no significant difference of pancreas-to-body weight ratios between the LWDHP-treated group and the untreated group. The ability of glucose tolerance was improved in the LWDHP-treated group. CONCLUSION: LWDHP can up-regulate the expression of bcl-2 and down-regulate the expression of Bax at transcription level, which maybe contribute to the anti-apoptosis effects of LWDHP.